Baruch D. Kuppermann
Professor of Ophthalmology and Biomedical Engineering; Chief, Retina Service; Vice-Chair, Clinical Research, Ophthalmology
|1) Ocular Manifestations of AIDS 2) Risk factors for the development of retinopathy of prematurity post partum 3) Photodynamic therapy for the treatment of choroidal melanomas|
After completing his Ph.D. in neuroscience at the California Institute of Technology (Cal Tech), Dr. Kuppermann went on to earn an M.D. at the University of Miami. He interned at LA County/USC Medical Center and did his residency in ophthalmology at USC’s Doheny Eye Institute. Dr. Kuppermann then went on to complete fellowships in Retina at both St. Joseph’s in Baltimore Maryland, and at the University of California, San Diego.
Following his fellowships he came to UCI and has been on faculty since 1992. He served as Acting Chairman of the Department of Ophthalmology at UCI from September 1995 to April 1996, and Interim Chairman from July 1, 1996 to December 1998. Currently he is a Professor and Chief of the Retina Service at UCI.
Dr. Kuppermann is the principal investigator at UCI for several multicenter national trials evaluating new drugs and devices for the treatment of diabetic retinopathy, age-related macular degeneration, and the ocular complications of AIDS. He is the national and international lead investigator for several of these trials. His primary area of research is drug delivery to the posterior segment of the eye, with special attention to the pharmacokinetics of the posterior segment. He has also developed models for viral retinal infections as well as for retinal angiogenesis and his research on these models using time release therapeutic agents may lead to new methods for the treatment of potentially blinding infections. In addition, Dr. Kuppermann has extensive research collaborations with pharmaceutical and biotechnology companies, serving as an advisor with a goal of bringing new treatments to patients for a variety of retinal diseases.
Dr Kuppermann is listed as one of the best doctors in America, and for the last several years in a row has been named as the "Best Ophthalmologist in Orange County" by Orange Coast Magazine. Dr. Kuppermann is a peer reviewer for the American Journal of Ophthalmology, Archives of Ophthalmology, Investigative Ophthalmology and Visual Science, Ophthalmology, Retina, Journal of Infectious Diseases, Lancet, and the Journal of Obstetrics and Gynecology.
|Kuppermann BD: Ocriplasmin Efficacy-An Analysis of Real-world Results from 2013 to 2015. European Ophthalmic Review. Touch Medical Media. September 2015. 141-144.|
|Erb MH, Lu SY, Kuppermann BD. Surgical Approaches to Uveitis. Pediatric Retina. Second Edition. Lippincott, Williams, & Wilkins. Chapter 55. September 2013.|
|Lu SY, Kuppermann BD: Retinal Surgery. Ophthalmic Microsurgery: Principles, Techniques, and Applications. Copyright © 2014 by Slack Incorporated. Chapter 10. Page 103-111.|
|Kuppermann BD: A New Approach to the Rhino in the Room. Cataract & Refractive Surgery Today. 2014 June; 57-58.|
|Smet MD, Kuppermann BD: Pharmacologic Vitreolysis: New Perspectives, Future Directions. Springer-Verlag Berlin Heidelberg 2014. Chapter 12; 113-117.|
|Narayanan R, Kuppermann BD; Lu S: Adding Corticosteroid Implants for Diabetic Eye Disease. Retinal Physician. 2012 March; 9(2):52-59.|
|Kaiser PK, Kuppermann BD: Bringing Retinal Disease Into Focus: A supplement based on proceedings of Retinal Disease Summit 2012. October 2012; 3-11.|
|Kuppermann BD: Diabetic Macular Edema. Critical Papers in the Management of Macular Edema in Retinal and Uveitic Diseases. Johns Hopkins Advanced Studies in Ophthalmology. February 2013; (10)1.|
|Kuppermann BD: Integrin Peptide Therapy for the Treatment of Vascular Eye Diseases. Retina Today. March 2013; 60-63.|
|Kuppermann BD: A New Approach to the Rhino in the Room. Retina Today. 2014 May/June; 79-80.|
|Kuppermann BD: A Dual-Mechanism Drug for Vitreoretinal Diseases. Retina Today. July/August 2015. 85-87.|
|Grants||“An evaluation of Intravitreal Ranibizumab for Bitreous Hemorrhage due to Porliferative Diabetic Retinopathy (protocol N)”. Jaeb. June 2010-Current.|
|“Development of an Office Based Real-time High Speed 3D Functional OCT System for Diagnosis of Retinal Diseases”. NIH-OCT Subaward. March 2011-Current.|
|“A Multicenter, Patient-masked, Safety extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System (Allergan 033D). Allergan. December 2010-Current.|
|“A 12 Month, Multicenter, Masked, Randomized,Controlled study to Assess the Safety and Efficacy of 700ug Ozurdex as Adjunctive Therapy to Lucentis compared with Lucentis Alone in the Treatment of Patients with Choroidal Neovascularization Secondary to AMD (Allergan 021). Allergan. November 2010-Current.|
|“Controlled, Double Masked, Randomized, Multicenter Study to Evaluate AL-78898A as a Treatment of Exudative AMD (RACE). Alcon Labs. August 2010-Current|
American Academy of Ophthalmology
American Society of Retina Specialists
Pan American Association of Ophthalmology
|Link to this profile||http://www.faculty.uci.edu/profile.cfm?faculty_id=2230|